Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Bamako, Mali: A Population-Based Cross-Sectional Study in September 2022.
Bamako
Mali
SARS‐CoV‐2 antibodies
associated factors
seroprevalence
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
15
05
2024
received:
08
05
2023
accepted:
31
05
2024
medline:
24
7
2024
pubmed:
24
7
2024
entrez:
24
7
2024
Statut:
ppublish
Résumé
The sero-epidemiological characteristics of SARS-CoV-2 infections in Mali are not yet well understood. This study assessed SARS-CoV-2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID-19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali. A cross-sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti-Spike (anti-S) and anti-RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R-Studio was used for the statistical analysis. The chi-squared (χ The sex ratio for female-to-male was 3.6:1. The most representative groups were the 20-29-year-olds (28.9%, n = 1043) and the 30-39-year-olds (26.9%, n = 967). The COVID-19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1-9 years old) and male sex were associated with lower SARS-CoV-2 antibody responses, whereas COVID-19 vaccinations were associated with increased antibody responses. This serosurvey demonstrated the high seroprevalence of SARS-CoV-2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.
Sections du résumé
BACKGROUND
BACKGROUND
The sero-epidemiological characteristics of SARS-CoV-2 infections in Mali are not yet well understood. This study assessed SARS-CoV-2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID-19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.
METHODS
METHODS
A cross-sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti-Spike (anti-S) and anti-RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R-Studio was used for the statistical analysis. The chi-squared (χ
RESULT
RESULTS
The sex ratio for female-to-male was 3.6:1. The most representative groups were the 20-29-year-olds (28.9%, n = 1043) and the 30-39-year-olds (26.9%, n = 967). The COVID-19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1-9 years old) and male sex were associated with lower SARS-CoV-2 antibody responses, whereas COVID-19 vaccinations were associated with increased antibody responses.
CONCLUSION
CONCLUSIONS
This serosurvey demonstrated the high seroprevalence of SARS-CoV-2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.
Substances chimiques
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13343Subventions
Organisme : WHO/Afro
ID : 2022/1267006-0
Organisme : WHO Unity Studies
Organisme : COVID-19 Solidarity Response Fund
Organisme : German Federal Ministry of Health
Informations de copyright
© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
H. D. Page Jeremy, M. K. Betsy, et al., “In Hunt for Covid‐19 Origin, Patient Zero Points to Second Wuhan Market,” Wall Street Journal 26 (2021): 02‐26T10:30:00Z.
E. Mahase, “China Coronavirus: WHO Declares International Emergency as Death Toll Exceeds 200,” BMJ 368 (2020): m408.
S. Erol, “Assessing the Impact of the Covid‐19 Pandemic on the Financial and Economic Structure Performance of Turkish Sea Freight Transport Sector,” Regional Studies in Marine Science 57 (2023): 102749.
P. van der Merwe, A. Saayman, and C. Jacobs, “Assessing the Economic Impact of COVID‐19 on the Private Wildlife Industry of South Africa,” Global Ecology and Conservation 28 (2021): e01633.
I. Kiseleva, E. Grigorieva, N. Larionova, M. Al Farroukh, and L. Rudenko, “COVID‐19 in Light of Seasonal Respiratory Infections,” Biology (Basel). 9, no. 9 (2020): 240.
Organization WH, Weekly Epidemiological Update on COVID‐19‐1 February 2023, (2023).
Organization WH, WHO Coronavirus (COVID‐19) Dashboard, (2023).
M. K. Njenga, J. Dawa, M. Nanyingi, et al., “Why Is there Low Morbidity and Mortality of COVID‐19 in Africa?” The American Journal of Tropical Medicine and Hygiene. 103, no. 2 (2020): 564–569.
R. G. Wamai, J. L. Hirsch, W. van Damme, et al., “What Could Explain the Lower COVID‐19 Burden in Africa Despite Considerable Circulation of the SARS‐CoV‐2 Virus?” International Journal of Environmental Research and Public Health 18, no. 16 (2021): 8638.
H. C. Lewis, H. Ware, M. Whelan, et al., “SARS‐CoV‐2 Infection in Africa: A Systematic Review and Meta‐Analysis of Standardised Seroprevalence Studies, From January 2020 to December 2021,” BMJ Global Health 7, no. 8 (2022): e008793.
Y. A. Adebisi, A. Rabe, and D. E. Lucero‐Prisno Iii, “COVID‐19 Surveillance Systems in African Countries,” Health Promotion Perspective 11, no. 4 (2021): 382–392.
S. D. Judson, J. Torimiro, D. M. Pigott, et al., “COVID‐19 Data Reporting Systems in Africa Reveal Insights for Future Pandemics,” Epidemiology and Infection 150 (2022): e119.
Mali MdlSedDSd, “Communique N°1050 du Ministère de la Santé et du Développement Social sur le suivi des actions de prévention et de riposte face à la maladie à coronavirus,” (2023), https://rbgy/cha2c.
E. Mathieu, H. Ritchie, L. Rodés‐Guirao, et al., “Mali: Coronavirus Pandemic Country Profile,” accessed August 8, 2023, https://rbgy/1z9f6.
A. Somboro, Y. Cissoko, I. Camara, et al., “High SARS‐CoV‐2 Seroprevalence Among Healthcare Workers in Bamako, Mali,” Viruses 14, no. 1 (2022): 102.
F. W. Temessadouno, J. G. Ndong, E. Gignoux, et al., “Seroprevalence of Anti‐SARS‐CoV‐2 Antibodies Among Blood Donors From December 2020 to June 2021 in Koutiala District, Mali,” PLOS Global Public Health 3, no. 1 (2023): e0001316.
L. C. Steinhardt, F. Ige, N. C. Iriemenam, et al., “Cross‐Reactivity of Two SARS‐CoV‐2 Serological Assays in a Setting Where Malaria Is Endemic,” Journal of Clinical Microbiology 59, no. 7 (2021): e0051421.
I. Bergeri, H. C. Lewis, L. Subissi, et al., “Early Epidemiological Investigations: World Health Organization UNITY Protocols Provide a Standardized and Timely International Investigation Framework During the COVID‐19 Pandemic,” Influenza and Other Respiratory Viruses 16, no. 1 (2022): 7–13.
Response H, “Situation Report of COVID‐19 in Mali (Rapport de situation COVID‐19 au Mali),” (2021), https://rbgy/jm88s.
J. Woodford, I. Sagara, A. Dicko, et al., “Severe Acute Respiratory Syndrome Coronavirus 2 Seroassay Performance and Optimization in a Population With High Background Reactivity in Mali,” The Journal of Infectious Diseases 224, no. 12 (2021): 2001–2009.
I. Sagara, J. Woodford, M. Kone, et al., “Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study,” Clinical Infectious Diseases 74, no. 6 (2022): 1030–1038.
N. S. Struck, E. Lorenz, C. Deschermeier, et al., “High Seroprevalence of SARS‐CoV‐2 in Burkina‐Faso, Ghana and Madagascar in 2021: A Population‐Based Study,” BMC Public Health 22, no. 1 (2022): 1676.
K. Hajissa, M. A. Islam, S. A. Hassan, A. R. Zaidah, N. Ismail, and Z. Mohamed, “Seroprevalence of SARS‐CoV‐2 Antibodies in Africa: A Systematic Review and Meta‐Analysis,” International Journal of Environmental Research and Public Health 19, no. 12 (2022): 7257.
S. Uyoga, I. M. O. Adetifa, H. K. Karanja, et al., “Seroprevalence of Anti–SARS‐CoV‐2 IgG Antibodies in Kenyan Blood Donors,” Science 371, no. 6524 (2021): 79–82.
A. L. Deutou Wondeu, B. M. Talom, G. Linardos, et al., “The COVID‐19 Wave Was Already Here: High Seroprevalence of SARS‐CoV‐2 Antibodies Among Staff and Students in a Cameroon University,” Journal of Public Health in Africa 14, no. 1 (2023): 2242.
J. Manning, I. Zaidi, C. Lon, et al., “SARS‐CoV‐2 Cross‐Reactivity in Prepandemic Serum from Rural Malaria‐Infected Persons, Cambodia,” Emerging Infectious Diseases 28, no. 2 (2022): 440–444.
A. Traoré, A. Guindo, D. Konaté, et al., “Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor‐Binding Domain, and Its Receptor‐Binding Motif in COVID‐19 Patients and Their Cross‐Reactivity With Pre‐COVID‐19 Samples From Malaria‐Endemic Areas,” Frontiers in Immunology 13 (2022): 856033.
S. Murray, A. Ansari, J. Frater, et al., “The Impact of Pre‐Existing Cross‐Reactive Immunity on SARS‐CoV‐2 Infection and Vaccine Responses,” Nature Reviews. Immunology 23 (2022): 304–316.
S. P. Weisberg, T. J. Connors, Y. Zhu, et al., “Distinct Antibody Responses to SARS‐CoV‐2 in Children and Adults Across the COVID‐19 Clinical Spectrum,” Nature Immunology 22, no. 1 (2021): 25–31.
C. A. Pierce, P. Preston‐Hurlburt, Y. Dai, et al., “Immune Responses to SARS‐CoV‐2 Infection in Hospitalized Pediatric and Adult Patients,” Science Translational Medicine 12, no. 564 (2020): eabd5487.
C. R. Consiglio, N. Cotugno, F. Sardh, et al., “The Immunology of Multisystem Inflammatory Syndrome in Children With COVID‐19,” Cell 183, no. 4 (2020): 968–981.e7.
S. Bunyavanich, A. Do, and A. Vicencio, “Nasal Gene Expression of Angiotensin‐Converting Enzyme 2 in Children and Adults,” Journal of the American Medical Association 323, no. 23 (2020): 2427–2429.
N. Gadi, S. C. Wu, A. P. Spihlman, and V. R. Moulton, “What's Sex Got to Do With COVID‐19? Gender‐Based Differences in the Host Immune Response to Coronaviruses,” Frontiers in Immunology 11 (2020): 2147.
B. Huang, Y. Cai, N. Li, et al., “Sex‐Based Clinical and Immunological Differences in COVID‐19,” BMC Infectious Diseases 21, no. 1 (2021): 647.
L. Palaiodimos, D. G. Kokkinidis, W. Li, et al., “Severe Obesity, Increasing Age and Male Sex Are Independently Associated With Worse in‐Hospital Outcomes, and Higher In‐Hospital Mortality, in a Cohort of Patients With COVID‐19 in the Bronx, New York,” Metabolism, Clinical and Experimental 108 (2020): 154262.
C. P. Tadiri, T. Gisinger, A. Kautzy‐Willer, et al., “The Influence of Sex and Gender Domains on COVID‐19 Cases and Mortality,” Canadian Medical Association Journal 192, no. 36 (2020): E1041–E1045.
F. Zeng, C. Dai, P. Cai, et al., “A Comparison Study of SARS‐CoV‐2 IgG Antibody Between Male and Female COVID‐19 Patients: A Possible Reason Underlying Different Outcome Between Sex,” Journal of Medical Virology 92, no. 10 (2020): 2050–2054.
D. De Vito, A. Di Ciaula, V. O. Palmieri, et al., “Reduced COVID‐19 Mortality Linked With Early Antibodies Against SARS‐CoV‐2, Irrespective of Age,” European Journal of Internal Medicine 98 (2022): 77–82.